$NVCR Hey fellow $NVCR crew, if you’re looking for another good growth opportunity, I’ve been following $XERS for over a year now. It was beaten down post-IPO and is now headed back up after some good PR on Friday. They have an interesting shelf-stable delivery system for medications as one of their proprietary systems and interesting meds in the pipeline for rare/orphan diseases. I’m in long with 8500 shares at 4.54 DCA, recently increased from 5k at 4.04. Definitely worth a look after you do your own due diligence!